MedTrace Logo

Effects of Liraglutide on Body Surface Gastric Mapping

NCT06500130 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-01-29

No results posted yet for this study

Summary

Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of liraglutide and subsequent washout.

Aim 2: Assessment of effect of liraglutide injection on gastrointestinal symptoms and gut-brain wellbeing (as measured by validated symptom App and Alimetry gut-brain wellness Scale, respectively) during an 13-day ramping dose of liraglutide and subsequent washout.

Conditions

  • Gastroparesis
  • Functional Dyspepsia
  • Chronic Nausea and Vomiting Syndrome
  • Healthy

Interventions

DEVICE

Body Surface Gastric Mapping

All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.

Sponsors & Collaborators

  • Alimetry

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2024-10-30
Completion
2024-11-30

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500130 on ClinicalTrials.gov